Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

34.90p
   
  • Change Today:
    -0.100p
  • 52 Week High: 71.80
  • 52 Week Low: 34.20
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 3,721,382
  • Market Cap: £188.60m
  • RiskGrade: 119

Alliance Pharma buys Asia-Pacific rights to Nizoral dandruff shampoo

By Josh White

Date: Tuesday 19 Jun 2018

LONDON (ShareCast) - (Sharecast News) - Speciality pharmaceutical company Alliance Pharma has agreed to acquire exclusive marketing rights to medical anti-dandruff shampoo brand Nizoral in the Asia-Pacific region from Johnson & Johnson subsidiary Janssen Pharmaceutica, it announced on Tuesday, for a total consideration of £60m.
The AIM-traded firm said the acquisition, which would boost Alliance's "successful and rapidly growing" APAC distributor business, was expected to be materially earnings-enhancing in the first full year of ownership.

Alliance said the acquisition would be funded by an underwritten equity placing of new ordinary shares in the capital of the company to raise gross proceeds of £34m, at an indicative placing price of 91p per share, to be confirmed pursuant to an accelerated bookbuild process, as well as by the draw down of £27.9m of a £35m extension of the group's debt facilities.

The placing was being conducted by means of an accelerated bookbuild process, which was launched immediately following Tuesday morning's announcement.

Rights to the Nizoral brand were being purchased in more than 15 countries including Japan, Thailand, South Korea, China and Pacific markets.

In 2017, the Nizoral rights achieved net sales of £18.5m in the APAC region, and taking into account Alliance's anticipated costs, the rights would have generated EBITDA on a pro forma basis of £7.1m in 2017.

Nizoral would represent Alliance's fourth 'international star brand', complementing 'Kelo-cote', 'MacuShield' and 'Vamousse'.

"Asia-Pacific is Alliance's fastest-growing region and we are delighted to strengthen the development of our APAC business through this earnings-enhancing acquisition of Nizoral, an excellent brand with a long medical heritage," said Alliance chief executive Peter Butterfield.

"Nizoral has significant sales, profits and growth potential in the APAC region and will become the fourth International Star brand in our product portfolio."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 34.90p
Change Today -0.100p
% Change -0.29 %
52 Week High 71.80
52 Week Low 34.20
Volume 3,721,382
Shares Issued 540.40m
Market Cap £188.60m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
84.56% above the market average84.56% above the market average84.56% above the market average84.56% above the market average84.56% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
69.61% below the market average69.61% below the market average69.61% below the market average69.61% below the market average69.61% below the market average
1.75% above the sector average1.75% above the sector average1.75% above the sector average1.75% above the sector average1.75% above the sector average
Income
9.02% above the market average9.02% above the market average9.02% above the market average9.02% above the market average9.02% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Growth
88.94% below the market average88.94% below the market average88.94% below the market average88.94% below the market average88.94% below the market average
83.78% below the sector average83.78% below the sector average83.78% below the sector average83.78% below the sector average83.78% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 25-Apr-2024

Time Volume / Share Price
16:35 34,082 @ 34.90p
16:35 111 @ 34.90p
16:35 1,254 @ 34.90p
16:35 1,641 @ 34.90p
16:35 2,071 @ 34.90p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page